The Ipsen Investment Case

FY 2021: Oncology sales highlights Cabometyx Єm sales 100 50 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 CABOMETYX® (cabozantinib) tablets FY 2021: +22.8% Strong volumes across most geographies TKI of choice in 2L RCC Combination in 1L RCC launched in Germany. Cabometyx 1L new-patient exit share now at 18% Reimbursement and launches in 1L RCC expected in other key E.U. countries in 2022 IPSEN Innovation for patient care All growth rates are at constant exchange rates. Absolute values are shown at actual exchange rates. TKI: tyrosine kinase inhibitor; 2L: second line; 1L: first line; RCC: renal cell carcinoma. Sources: IQVIA MIDAS / GERS (FR), KANTAR. 22 22

View entire presentation